ALT Levels After Completion of Immunosuppressive Therapy Accompanying BMT With and Without HGV
| Patient No. . | BMT . | Conditioning Regimen . | Donor Exposure (person) . | Transfused RBC (U) . | Ferritin (ng/dL) . | During HGV Viremic Period . | |
|---|---|---|---|---|---|---|---|
| Maximum ALT (IU/L) . | Mean ALT (IU/L) . | ||||||
| HGV-infected population (n = 6) | |||||||
| 3 | Related | TBI + L-PAM + VP | 309 | 86 | 1,100 | 91 | 29.8 ± 6.1 |
| 5 | Related | TBI + L-PAM + BU | 26 | 20 | 620 | 82 | 38.8 ± 58.1 |
| 6 | Related | TBI + L-PAM + ATG | 55 | 23 | 390 | 77 | 23.5 ± 16.8 |
| 11 | Related | ALG + CY | 46 | 15 | 1,440 | 179 | 118.5 ± 39.2 |
| 12 | Unrelated | TBI + L-PAM + VP | 126 | 39 | 280 | 55 | 27.3 ± 13.6 |
| 14 | Unrelated | TBI + CY | 31 | 8 | >500 | 44 | 17.4 ± 8.6 |
| Mean ± SD | 98.8 ± 109.1 | 31.8 ± 28.54-150 | 1,242 ± 1,188 | 88.0 ± 19.64-151 | 44.9 ± 15.6 | ||
| HGV uninfected population (n = 10) | |||||||
| 22 | Autologous | CP + VP + L-PAM | 34 | 12 | — | 27 | 12.1 ± 6.3 |
| 23 | Unrelated | TBI + CY + ATG | 16 | 10 | — | 30 | 18.7 ± 4.5 |
| 24 | Related | BU + BP + CY | 77 | 12 | 2,500 | 29 | 15.6 ± 2.2 |
| 25 | Related | TBI + CY | 15 | 5 | 270 | 65 | 18.4 ± 10.6 |
| 26 | Related | TBI + L-PAM | 67 | 17 | 650 | 28 | 15.4 ± 3.8 |
| 27 | Related | TBI + L-PAM | 16 | 8 | — | 21 | 15.6 ± 2.8 |
| 28 | Related | BU + VP | 56 | 25 | 3,000 | 46 | 26.9 ± 9.3 |
| 29 | Related | TBI + VP + L-PAM | 15 | 3 | 380 | 34 | 23.8 ± 5.8 |
| 30 | Related | BU + L-PAM | 32 | 12 | — | 46 | 35.3 ± 10.4 |
| 31 | Related | TBI + CY + HDAC + ATG | 18 | 0 | 650 | 46 | 27.5 ± 10.0 |
| Mean ± SD | 34.6 ± 23.7 | 10.4 ± 7.2 | 722 ± 452 | 37.2 ± 4.2 | 20.9 ± 2.3 | ||
| Patient No. . | BMT . | Conditioning Regimen . | Donor Exposure (person) . | Transfused RBC (U) . | Ferritin (ng/dL) . | During HGV Viremic Period . | |
|---|---|---|---|---|---|---|---|
| Maximum ALT (IU/L) . | Mean ALT (IU/L) . | ||||||
| HGV-infected population (n = 6) | |||||||
| 3 | Related | TBI + L-PAM + VP | 309 | 86 | 1,100 | 91 | 29.8 ± 6.1 |
| 5 | Related | TBI + L-PAM + BU | 26 | 20 | 620 | 82 | 38.8 ± 58.1 |
| 6 | Related | TBI + L-PAM + ATG | 55 | 23 | 390 | 77 | 23.5 ± 16.8 |
| 11 | Related | ALG + CY | 46 | 15 | 1,440 | 179 | 118.5 ± 39.2 |
| 12 | Unrelated | TBI + L-PAM + VP | 126 | 39 | 280 | 55 | 27.3 ± 13.6 |
| 14 | Unrelated | TBI + CY | 31 | 8 | >500 | 44 | 17.4 ± 8.6 |
| Mean ± SD | 98.8 ± 109.1 | 31.8 ± 28.54-150 | 1,242 ± 1,188 | 88.0 ± 19.64-151 | 44.9 ± 15.6 | ||
| HGV uninfected population (n = 10) | |||||||
| 22 | Autologous | CP + VP + L-PAM | 34 | 12 | — | 27 | 12.1 ± 6.3 |
| 23 | Unrelated | TBI + CY + ATG | 16 | 10 | — | 30 | 18.7 ± 4.5 |
| 24 | Related | BU + BP + CY | 77 | 12 | 2,500 | 29 | 15.6 ± 2.2 |
| 25 | Related | TBI + CY | 15 | 5 | 270 | 65 | 18.4 ± 10.6 |
| 26 | Related | TBI + L-PAM | 67 | 17 | 650 | 28 | 15.4 ± 3.8 |
| 27 | Related | TBI + L-PAM | 16 | 8 | — | 21 | 15.6 ± 2.8 |
| 28 | Related | BU + VP | 56 | 25 | 3,000 | 46 | 26.9 ± 9.3 |
| 29 | Related | TBI + VP + L-PAM | 15 | 3 | 380 | 34 | 23.8 ± 5.8 |
| 30 | Related | BU + L-PAM | 32 | 12 | — | 46 | 35.3 ± 10.4 |
| 31 | Related | TBI + CY + HDAC + ATG | 18 | 0 | 650 | 46 | 27.5 ± 10.0 |
| Mean ± SD | 34.6 ± 23.7 | 10.4 ± 7.2 | 722 ± 452 | 37.2 ± 4.2 | 20.9 ± 2.3 | ||
The values of mean ALT represent the average of the mean ALT values of each patient measured during each month of the hospital course.
Abbreviations: TBI, total body irradiation; L-PAM, melphalan; BU, busulfan; VP, etoposide; ALG, antilymphocyte globulin; ATG, antithymocyte globulin; CY, cyclophosphamide; HDAC, high-dose cytosine arabinoside.
P = .0366 HGV-infected versus uninfected.
P = .0064 HGV-infected versus uninfected.